VES-001

Vesper Bio has commenced a Phase Ib/IIa clinical trial, named SORT-IN-2, to assess VES001 in asymptomatic patients with GRN mutations causing frontotemporal dementia (FTD).

Vesper Bio announced positive results from its Phase 1 clinical trial of VES001, an oral drug for frontotemporal dementia (FTD) linked to GRN mutations.

Vesper Bio's VES001 demonstrated a favorable safety and tolerability profile in a Phase I trial involving 78 healthy subjects.